Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.4352W HIGH $61.00
Volume
9.91 K
Value Traded
48.56 K
Short % Float
0.79%
Days to Cover
4.0
-12.44%Week
-14.21%1 Month
-30.45%3 Month
-21.4%6 Month
-85.67%5 Year
-85.67%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
124.71 M
EPS (TTM)
-0.06
P/E Ratio
-
Ent. Value
180.83 M
Total Shares
74.23 M
Float Shares
28.06 M
Insiders
62.20%
Institutions
0.69%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
MENS Catalyst Timeline
Dated clinical, regulatory and corporate events for Jyong Biotech Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Jyong Biotech Ltd.
11Total events
4Upcoming
4Tier-1 (high impact)
2026 to 2026Coverage
Upcoming catalysts 2
TBD
T1NDA Submission
Subscribe to view catalyst details
TBD
T1Partnership / License
Subscribe to view catalyst details
Event history 6
●R&D DayPresentation
Jyong Biotech two-day investor events in Silicon Valley and Irvine, California
●Manufacturing MilestoneCMC / Inspection
Jyong Biotech submits Texas facility and operations plan to local government authorities
●R&D DayPresentation
Jyong Biotech to participate in StockFan Virtual Investor Non-Deal Roadshow
●Oral PresentationBotresoPresentation
Jyong Biotech presented Botreso at BIO 2026 International Convention
benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS)source ↗
●Partnership / LicenseBotresoCorporate
Global licensing discussions for Botreso at BIO 2026
benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS)source ↗
Past FDA Catalysts and PDUFA Decisions
How MENS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 97%
Micro Cap(rank 637 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every MENS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Botreso® | BPH | Phase 3 | 2026-04-28 | no drug-related serious adverse events were observedRead More | Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug PortfolioRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MENS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in MENS for Q2 2026. | ||||
MENS Institutional Ownership Trends
MENS Short Interest
Shares sold short, counted twice a month.
0.79%
Short % of Float
of tradable shares sold short
222.1K
Shares Sold Short
-9.5% vs prior count
4.0 Moderate
Days to Cover
trading days of normal volume to buy every short share back
55.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MENS ranks across every disease it competes in
Competitive Position is a premium feature
See how MENS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMENS News
MENSJyong Biotech to Host Two-Day Investor Events in Silicon Valley and Irvine, California
Jyong Biotech Ltd. will host two investor events on October 24 and 25, 2026, in California. The meetings will take place in Mountain View and Irvine, where management will discuss recent operational highlights and strategic initiatives. The company specializes in developing plant-derived therapeutics for urinary system diseases.
Read more →MENSJyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates
Jyong Biotech Ltd. has announced plans to establish a manufacturing facility in Texas to support its U.S. operations and potential commercialization of its drug candidates. The decision is based on favorable factors such as competitive land costs and tax incentives. The company aims to target significant patient populations for its investigational therapies, although it currently has no approved products.
Read more →MENSJyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow
Jyong Biotech Ltd. announced its participation in the StockFan Virtual Investor Non-Deal Roadshow scheduled for September 6-7, 2026. The event will be conducted in Mandarin and English, allowing global access for investors. Jyong Biotech focuses on developing plant-derived therapeutics, particularly for urinary system diseases, and aims to enhance its market presence through this event.
Read more →MENSJyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
Jyong Biotech Ltd. is focusing on global licensing partnerships to address the growing medical needs in the urology sector, specifically for Benign Prostatic Hyperplasia (BPH). The company has advanced its botanical drug candidate, Botreso®, to Phase III clinical trials and aims to meet the significant unmet medical needs in BPH treatments. The global BPH market is expected to grow substantially, highlighting the potential for Jyong Biotech's innovations.
Read more →MENS▲ +8.3%on this news
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention
Jyong Biotech Ltd. participated in the BIO 2026 International Convention, showcasing its botanical drug candidate, Botreso® (API-1), aimed at treating benign prostatic hyperplasia and lower urinary tract symptoms. The company is advancing global licensing discussions and preparing for New Drug Application submissions. With a focus on safety and efficacy, Jyong Biotech aims to expand its market presence in the U.S., Europe, and Asia.
Read more →MENSJyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview
Jyong Biotech's CEO, Fu-Feng Kuo, outlined the company's FDA pathway and global strategy in a PharmaBoardroom interview. The firm is advancing its lead botanical drug, Botreso®, aimed at treating benign prostatic hyperplasia (BPH), and is preparing for a New Drug Application submission. The company emphasizes its commitment to developing effective treatments with low side effects, while also exploring partnerships for its Prostate Cancer Prevention asset.
Read more →MENSJyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
Jyong Biotech Ltd. has filed its annual report on Form 20-F for the fiscal year 2025 with the SEC. The report includes audited financial statements and is available on the company’s investor relations website. Jyong Biotech specializes in developing plant-derived therapeutics, particularly for urinary system diseases, and aims to meet health needs with innovative drugs.
Read more →MENSJyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio
Jyong Biotech has advanced its market access strategies for its innovative botanical drugs, Botreso® and PCP, following successful clinical trials. Both products demonstrate significant safety and efficacy, particularly in addressing prostate health issues. The company aims to leverage its unique positioning and technological advantages to capture a growing market for BPH treatments.
Read more →MENSJyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2
Jyong Biotech has updated on its innovative drug MCS®-2, which is the first oral botanical new drug to complete Phase III trials for benign prostatic hyperplasia (BPH). The drug has shown excellent safety and is positioned to meet a significant market need for effective BPH treatments. Jyong Biotech emphasizes its commitment to innovation and regulatory compliance as it prepares for commercialization.
Read more →MENSJyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia
Jyong Biotech has reported successful Phase II trial results for MCS-8, showing a 27.3% reduction in prostate cancer incidence among high-risk subjects. The trial also revealed significant metabolic benefits, including improved lipid profiles. The company is pursuing commercialization in Asia through strategic partnerships, positioning itself as a leader in preventative medicine.
Read more →MENS▼ -7.8%on this news· ran to -18% by day 3
Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value
Jyong Biotech's Phase II trial results for MCS-8 indicate promising efficacy in prostate cancer prevention and improved metabolic indicators. The study showed a 27.3% reduction in overall prostate cancer incidence and favorable trends in disease progression. The drug demonstrated a good safety profile with no serious adverse events, supporting its potential for long-term use.
Read more →MENSJYONG BIOTECH LIMITED UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (in thousand US Dollars, except share and per share data) As of
JYONG Biotech Limited released its unaudited interim condensed consolidated financial results for the six months ending June 30, 2025. The company reported an increase in net loss from $1,326k in 2024 to $1,252k. Additionally, there was a notable rise in total comprehensive loss, which increased from $853k to $2,411k. The shareholders' deficit also widened, reaching $22,472k as of June 30, 2025.
Read more →MENSJyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering
Jyong Biotech Ltd. has announced the pricing of its initial public offering (IPO) at $7.50 per share, aiming to raise approximately $20 million. The company focuses on developing plant-derived drugs for urinary system diseases and has secured approval for its shares to be listed on the Nasdaq under the ticker 'MENS'. Proceeds from the IPO will be allocated to various clinical trial phases, enhancing its pipeline of botanical drug candidates. The offering is expected to close soon, subject to customary conditions being met.
Read more →About Jyong Biotech Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next MENS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime